Clinical risk assessment for recurrence and metastasis is not enough to avoid adjuvant chemotherapy. Genomic assessment can help to identify those at higher risk that benefit from treatments.
ESMO 2017: One in four small and early-stage breast cancers can be aggressive and benefit from adjuvant chemotherapy
(...)
Информация доступна только для зарегистрированных пользователей. Чтобы продолжить, войдите на сайт или зарегистрируйтесь бесплатно.
